


[008] Anxiety disorders are disorders characterized by fear, worry, and uneasiness, usually generalized and unfocused as an overreaction to a situation. Anxiety disorders differ in the situations or types of objects that induce fear, anxiety, or avoidance behavior, and the associated cognitive ideation. Anxiety differs from fear in that anxiety is an emotional response to a perceived future threat while fear is associated with a perceived or real immediate threat. They also differ in the content of the associated thoughts or beliefs.

SUMMARY


[009] While medications exist for some examples of these diseases, there remains a need for effective treatments for various neurological and psychiatric disorders, including mood disorders such as bipolar and related disorders, psychosis and schizophrenia. For example, while mood stabilizers such as lithium and valproate, antidepressants and antipsychotic drugs are used to treat mood disorders, more effective medications are necessary. And current antipsychotics may be successful in treating the positive symptoms of schizophrenia but fare less well for the negative and cognitive symptoms. Additionally, current antidepressants are typically effective only for a proportion of patients suffering from depression.

[09a] In one aspect, the present disclosure provides a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

A is



m is 0, 1, or 2;

n1 is 1, 2, or 3;

n₂ is 0 or 1;

n₃ is 0 or 1;

R is -H or C₁-C₃ alkyl;

R^a is -H or C₁-C₃ alkyl;

5 R¹, R², R³, and R⁴ are independently -H, halo, -OH, -NH₂, C₁-C₃ alkyl, -OR⁷, -NHR⁷, -N(R⁷)R⁷, -CN, phenyl, or 5- or 6- membered heteroaryl, wherein:

each instance of R⁷ independently is unsubstituted C₁-C₂ alkyl or C₁-C₂ alkyl substituted with 1-3 halo,

each instance of C₁-C₃ alkyl independently is unsubstituted or substituted with 1-3 halo,

and

the phenyl or heteroaryl is unsubstituted or substituted with 1 or 2 groups independently selected from halo, -OH, -OCH₃, -OCF₃, -NH₂, -NH(CH₃), -N(CH₃)₂, -CH₃, ethyl, -CF₃, and -CN,

optionally wherein

two adjacent instances of R¹, R², R³, and R⁴ together form -O-CH₂-O-, -O-CH(CH₃)-O-, -O-C(CH₃)₂-O-, -O-CH₂-CH₂-O-, or -O-C(CH₃)₂-C(CH₃)₂-O-;


each instance of R⁵ independently is halo, -CH₃, or ethyl;

each instance of R⁶ independently is halo, -CH₃, ethyl or -OH;


w is 0, 1, or 2; and

Z is C or O;

provided that the compound is not:



[09b] In another aspect, the present disclosure provides a compound of the formula:



3b

or a pharmaceutically acceptable salt thereof, wherein:

m is 0, 1, or 2;

R is -H or C₁-C₃ alkyl;

R^a is -H or C₁-C₃ alkyl;

5 R¹, R², R³, and R⁴ are independently -H, halo, -OH, -NH₂, C₁-C₃ alkyl, -OR⁷, -NHR⁷, -N(R⁷)R⁷, -CN, phenyl, or 5- or 6- membered heteroaryl, wherein:

each instance of R⁷ independently is unsubstituted C₁-C₂ alkyl or C₁-C₂ alkyl substituted with 1-3 halo,

10 each instance of C₁-C₃ alkyl independently is unsubstituted or substituted with 1-3 halo, and

the phenyl or heteroaryl is unsubstituted or substituted with 1 or 2 groups independently selected from halo, -OH, -OCH₃, -OCF₃, -NH₂, -NH(CH₃), -N(CH₃)₂, -CH₃, ethyl, -CF₃, and -CN,

optionally wherein


15 two adjacent instances of R¹, R², R³, and R⁴ together form -O-CH₂-O-, -O-CH(CH₃)-O-, -O-C(CH₃)₂-O-, -O-CH₂-CH₂-O-, or -O-C(CH₃)₂-C(CH₃)₂-O-;

each instance of R⁵ independently is halo, -CH₃, or ethyl;


each instance of R⁶ independently is halo, -CH₃, ethyl or -OH;

w is 0, 1, or 2; and

20 provided that the compound is not:




[009c] In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

25 **[009d]** In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

[009e] In another aspect, the present disclosure provides a compound:




5 or a pharmaceutically acceptable salt thereof.

[009f] In another aspect, the present disclosure provides a compound:



or a pharmaceutically acceptable salt thereof.


[009g] In another aspect, the present disclosure provides a compound:



10


or a pharmaceutically acceptable salt thereof.

[009h] In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

[009i] In another aspect, the present disclosure provides a compound:




5 or a pharmaceutically acceptable salt thereof.

[009j] In another aspect, the present disclosure provides a compound:



or a pharmaceutically acceptable salt thereof.


[009k] In another aspect, the present disclosure provides a compound:



10


or a pharmaceutically acceptable salt thereof.

[009l] In another aspect, the present disclosure provides a compound:



or a pharmaceutically acceptable salt thereof.


15 **[009m]** In another aspect, the present disclosure provides a compound:



or a pharmaceutically acceptable salt thereof.


3e

[009n] In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

[009o] In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

[009p] In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

[009q] In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

[009r] In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

[009s] In another aspect, the present disclosure provides a compound:




or a pharmaceutically acceptable salt thereof.

[009t] In another aspect, the present disclosure provides a compound:




5 or a pharmaceutically acceptable salt thereof.

[009u] In another aspect, the present disclosure provides a compound:



or a pharmaceutically acceptable salt thereof.


[009v] In another aspect, the present disclosure provides a compound:



10

or a pharmaceutically acceptable salt thereof.

[010] In some examples, the present disclosure encompasses the insight that compounds of Formula (I):



and pharmaceutically acceptable salts thereof, wherein A, R^a, R¹, R², R³, R⁴, R⁶, w and n1 are defined and described herein, are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.


5 **[011]** Also provided herein are methods for the treatment of various neurological and psychiatric disorders using the compounds and compositions provided herein.

10 **[011a]** In yet another aspect, the present disclosure provides a composition comprising a compound as described herein, or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

15 **[011b]** In yet another aspect, the present disclosure provides the compound as described herein, or a pharmaceutically acceptable salt thereof, or a composition as described herein for use in therapy.


20 **[011c]** In yet another aspect, the present disclosure provides a use of a compound as described herein, or a pharmaceutically acceptable salt thereof, or a composition as described herein, in the manufacture of a medicament for treating a neurological or psychiatric disorder in a patient.

[011d] In yet another aspect, the present disclosure provides a compound selected from



3h


[011e] In yet another aspect, the present disclosure provides a process for preparing a compound of formula




or a pharmaceutically acceptable salt thereof, comprising:

5



a) combining




with an acid to form



b) separating




into




and

c) isolating




[011f] In yet another aspect, the present disclosure provides a process for preparing a compound of formula

10




or a pharmaceutically acceptable salt thereof, comprising:

3i




[011g] In yet another aspect, the present disclosure provides a process for preparing a


5 compound of formula



or a pharmaceutically acceptable salt thereof, comprising:




3j




c) isolating

[011h] In yet another aspect, the present disclosure provides a process for preparing a compound of formula




5 or a pharmaceutically acceptable salt thereof, comprising:




a) combining


with an acid to form




b) separating



into




and




; and

c) isolating




WHAT IS CLAIMED IS:

1. A compound of formula I:



5 or a pharmaceutically acceptable salt thereof, wherein:

A is



m is 0, 1, or 2;

n1 is 1, 2, or 3;

10 n2 is 0 or 1;

n3 is 0 or 1;

R is -H or C₁-C₃ alkyl;

R^a is -H or C₁-C₃ alkyl;

R¹, R², R³, and R⁴ are independently -H, halo, -OH, -NH₂, C₁-C₃ alkyl, -OR⁷, -NHR⁷,

15 -N(R⁷)R⁷, -CN, phenyl, or 5- or 6- membered heteroaryl, wherein:

each instance of R⁷ independently is unsubstituted C₁-C₂ alkyl or C₁-C₂ alkyl
substituted with 1-3 halo,

each instance of C₁-C₃ alkyl independently is unsubstituted or substituted with
1-3 halo,

20 and

the phenyl or heteroaryl is unsubstituted or substituted with 1 or 2 groups
independently selected from halo, -OH, -OCH₃, -OCF₃, -NH₂, -NH(CH₃),
-N(CH₃)₂, -CH₃, ethyl, -CF₃, and -CN,

optionally wherein

25 two adjacent instances of R¹, R², R³, and R⁴ together form -O-CH₂-O-,
-O-CH(CH₃)-O-, -O-C(CH₃)₂-O-, -O-CH₂-CH₂-O-, or -O-C(CH₃)₂-C(CH₃)₂-O-;

each instance of R⁵ independently is halo, -CH₃, or ethyl;


each instance of R^6 independently is halo, $-CH_3$, ethyl or $-OH$;

w is 0, 1, or 2; and


Z is C or O;

provided that the compound is not:

5




2. The compound of claim 1 of formula (Ia):



or a pharmaceutically acceptable salt thereof.


3. The compound of claim 1 of formula (Ib):



10

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 of formula (Ic):



or a pharmaceutically acceptable salt thereof.

15

5. The compound of claim 1 of formula (Id):



or a pharmaceutically acceptable salt thereof.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein Z is C.

- 5 7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein n₂ is 0 and n₃ is 0.

8. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein one of n2 and n3 is 0 and the other is 1.

9. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof,
10 wherein n2 is 1 and n3 is 1.

10. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein n2 is 1 and Z is O.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein n_3 is 1.

12. The compound of claim 1 of formula (I-C):




or a pharmaceutically acceptable salt thereof.


13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein n1 is 1.

14. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein n1 is 2.

15. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein n_1 is 3.
16. A compound of the formula:




- 5 or a pharmaceutically acceptable salt thereof, wherein:
- m is 0, 1, or 2;
- R is -H or C_1 - C_3 alkyl;
- R^a is -H or C_1 - C_3 alkyl;
- R^1 , R^2 , R^3 , and R^4 are independently -H, halo, -OH, -NH₂, C_1 - C_3 alkyl, -OR⁷, -NHR⁷, -
- 10 N(R⁷)R⁷, -CN, phenyl, or 5- or 6- membered heteroaryl, wherein:
- each instance of R⁷ independently is unsubstituted C_1 - C_2 alkyl or C_1 - C_2 alkyl substituted with 1-3 halo,
- each instance of C_1 - C_3 alkyl independently is unsubstituted or substituted with 1-3 halo, and
- 15 the phenyl or heteroaryl is unsubstituted or substituted with 1 or 2 groups independently selected from halo, -OH, -OCH₃, -OCF₃, -NH₂, -NH(CH₃), -N(CH₃)₂, -CH₃, ethyl, -CF₃, and -CN,
- optionally wherein
- two adjacent instances of R^1 , R^2 , R^3 , and R^4 together form -O-CH₂-O-,
- 20 -O-CH(CH₃)-O-, -O-C(CH₃)₂-O-, -O-CH₂-CH₂-O-, or -O-C(CH₃)₂-C(CH₃)₂-O-;
- each instance of R^5 independently is halo, -CH₃, or ethyl;
- each instance of R^6 independently is halo, -CH₃, ethyl or -OH;
- w is 0, 1, or 2; and
- provided that the compound is not:























17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein at least two of R^1 , R^2 , R^3 , and R^4 are -H.
18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein at least three of R^1 , R^2 , R^3 , and R^4 are -H.
- 5 19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein the 5- or 6- membered heteroaryl has at least 1 nitrogen ring atom and is unsubstituted or substituted with 1 group selected from halo, -OH, -OCH₃, -OCF₃, -NH₂, -NH(CH₃), -N(CH₃)₂, -CH₃, ethyl, -CF₃, and -CN.
- 10 20. The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein the heteroaryl is unsubstituted pyridyl, pyrimidinyl, pyrrolyl, pyrazolyl, isoxazolyl, imidazolyl, or oxazolyl.
21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein the heteroaryl is unsubstituted pyridyl or isoxazolyl.
- 15 22. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein two adjacent instances of R^1 , R^2 , R^3 , and R^4 together form -O-CH₂-O-, -O-CH(CH₃)-O-, or -O-C(CH₃)₂-O-.
23. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein two adjacent instances of R^1 , R^2 , R^3 , and R^4 together form -O-CH₂-O-.
- 20 24. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , and R^4 are independently -H, halo, C₁-C₃ alkyl, -OR⁷ or -CN.
25. The compound of any of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , and R^4 are independently -H, -F, -CH₃, -OCH₃, or -CN.
26. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R^a is -H.
- 25 27. The compound of any one of claims 1 to 26, or a pharmaceutically acceptable salt thereof, wherein R is -H.
28. The compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, wherein R⁵ is -F or -CH₃.
- 30 29. The compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, wherein R⁶ is -F or -CH₃.













30. The compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-CH_3$.
31. The compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, wherein m is 0.
- 5 32. The compound of any one of claims 1 to 31, or a pharmaceutically acceptable salt thereof, wherein w is 0.
33. The compound of any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-F$ or $-CH_3$.
- 10 34. The compound of claim 1 selected from those depicted in Table 1, or a pharmaceutically acceptable salt thereof













TABLE 1













 I-1	 I-2
---	---













 I-3	 I-4
 I-5	 I-6
 I-7	 I-8
 I-9	 I-10
 I-11	 I-12
 I-13	 I-14













 I-15	 I-16
 I-21	 I-22
 I-23	 I-24
 I-25	 I-26













 I-27	 I-28
 I-29	 I-30
 I-31	 I-32
 I-33	 I-34
 I-35	 I-36
 I-37	 I-38

 I-39	 I-40
 I-41	 I-42
 I-43	 I-44
 I-45	 I-46
 I-47	 I-48
 I-49	 I-50













 I-51	 I-52
 I-53	 I-54
 I-55	 I-56
 I-57	 I-58
 I-59	 I-60
 I-61	 I-62












 I-63	 I-64
 I-65	 I-66
 I-67	 I-68
 I-69	 I-70
 I-71	 I-72
 I-73	 I-74













 I-75	 I-76
 I-77	 I-78
 I-79	 I-80
 I-81	 I-82
 I-83	 I-84
 I-85	 I-86

 I-87	 I-88
 I-89	 I-90
 I-91	 I-92
 I-93	 I-94
 I-95	 I-96
 I-97	 I-98


 I-99	 I-100
 I-101	 I-102
 I-103	 I-104
 I-105	 I-106
 I-107	 I-108
 I-109	 I-110

 I-111	 I-112
 I-113	 I-114
 I-115	 I-116
 I-117	 I-118
 I-119	 I-120
 I-121	 I-122

 I-123	 I-124
 I-125	 I-126
 I-127	 I-128
 I-129	 I-130
 I-131	 I-132
 I-133	


 I-134	 I-135
 I-136	 I-137
 I-138	 I-139
 I-140	 I-141
 I-142	 I-143
 I-144	 I-145

35. A compound:




or a pharmaceutically acceptable salt thereof.

5 36. The compound of claim 35 selected from:




or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof.

37. A compound:




or a pharmaceutically acceptable salt thereof.

38. A compound:




or a pharmaceutically acceptable salt thereof.

39. A compound:




or a pharmaceutically acceptable salt thereof.

10 40. A compound:




or a pharmaceutically acceptable salt thereof.

41. A compound:




or a pharmaceutically acceptable salt thereof.

42. The compound of claim 41, selected from:




or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof.

43. A compound:




10 or a pharmaceutically acceptable salt thereof.

44. A compound:




or a pharmaceutically acceptable salt thereof.

15 45. A compound:




or a pharmaceutically acceptable salt thereof.

46. A compound:




or a pharmaceutically acceptable salt thereof.

47. A compound:




or a pharmaceutically acceptable salt thereof.

48. The compound of claim 47, selected from:




or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof.

49. A compound:




or a pharmaceutically acceptable salt thereof.

50. A compound:




or a pharmaceutically acceptable salt thereof.

51. A compound:




or a pharmaceutically acceptable salt thereof.

52. A compound:




or a pharmaceutically acceptable salt thereof.

53. A compound:




or a pharmaceutically acceptable salt thereof.

54. The compound of claim 53, selected from:




or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof.

55. A compound:




or a pharmaceutically acceptable salt thereof.

56. A compound:




or a pharmaceutically acceptable salt thereof.

5 57. A compound:



or a pharmaceutically acceptable salt thereof.

58. A compound:



10 or a pharmaceutically acceptable salt thereof.

59. A composition comprising a compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

15 60. The compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, or a composition according to claim 59 for use in therapy.


61. Use of a compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, or a composition according to claim 59, in the manufacture of a medicament for treating a neurological or psychiatric disorder in a patient.

62. The use of claim 61, wherein the neurological or psychiatric disorder is major depression, schizophrenia, bipolar disorder, obsessive compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), mania, or psychosis.


63. The use of claim 61, wherein the neurological or psychiatric disorder is bipolar disorder, mania, psychosis, or schizophrenia.

64. The use of claim 61, wherein the neurological or psychiatric disorder is bipolar disorder.


65. A compound selected from





66. A process for preparing a compound of formula




or a pharmaceutically acceptable salt thereof, comprising:







67. A process for preparing a compound of formula



5 or a pharmaceutically acceptable salt thereof, comprising:



68. A process for preparing a compound of formula




or a pharmaceutically acceptable salt thereof, comprising:

- a) combining
-
- with an acid to form
-
- b) separating
-
- into
-
- and
-
- c) isolating
-

5

69. A process for preparing a compound of formula



or a pharmaceutically acceptable salt thereof, comprising:

- a) combining
-
- with an acid to form
-

